Therma Bright Secures New Customer Initial Purchase Order, Signaling Market Confidence
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) has secured a new customer with an initial purchase order for 200 units of its Venowave VW5 product. The order comes from a key distributor in the Durable Medical Equipment sector, with potential for significant follow-on orders following a successful market launch over the next two months.
The company also announced two debt settlements: issuance of 2,000,000 common shares at $0.05 per share to settle $100,000 debt, and a proposed settlement of $24,000 debt through 676,000 common shares at $0.0355 per share.
Venowave is a Medicare and Medicaid-eligible device that enhances vascular and lymphatic flow in lower limbs. This FDA-designated Durable Medical Equipment operates on a rechargeable 1.5V NiMH AA battery and is designed for multi-patient use.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ha acquisito un nuovo cliente con un ordine iniziale di 200 unità del suo prodotto Venowave VW5. L'ordine proviene da un distributore chiave nel settore dei dispositivi medici durevoli, con potenziale per ordini successivi significativi a seguito di un lancio di successo sul mercato nei prossimi due mesi.
L'azienda ha inoltre annunciato due accordi di estinzione del debito: l'emissione di 2.000.000 di azioni ordinarie a 0,05$ ciascuna per saldare un debito di 100.000$, e una proposta di estinzione di un debito di 24.000$ tramite 676.000 azioni ordinarie a 0,0355$ ciascuna.
Venowave è un dispositivo idoneo a Medicare e Medicaid che migliora il flusso vascolare e linfatico agli arti inferiori. Questo dispositivo medico durevole, approvato dalla FDA, funziona con una batteria ricaricabile NiMH AA da 1,5V ed è progettato per l'uso multi-paziente.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ha asegurado un nuevo cliente con una orden inicial de compra de 200 unidades de su producto Venowave VW5. El pedido proviene de un distribuidor clave en el sector de Equipos Médicos Duraderos, con potencial para pedidos adicionales significativos tras un exitoso lanzamiento en el mercado durante los próximos dos meses.
La compañía también anunció dos acuerdos de liquidación de deuda: emisión de 2,000,000 acciones ordinarias a $0.05 por acción para saldar una deuda de $100,000, y una propuesta de liquidación de una deuda de $24,000 mediante 676,000 acciones ordinarias a $0.0355 por acción.
Venowave es un dispositivo elegible para Medicare y Medicaid que mejora el flujo vascular y linfático en las extremidades inferiores. Este equipo médico duradero, aprobado por la FDA, funciona con una batería recargable NiMH AA de 1.5V y está diseñado para uso multi-paciente.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF)는 자사의 Venowave VW5 제품 200대에 대한 초기 구매 주문을 확보했습니다. 이 주문은 내구성 의료기기 분야의 주요 유통업체로부터 왔으며, 향후 두 달간 성공적인 시장 출시 후 상당한 추가 주문 가능성이 있습니다.
회사는 또한 두 건의 부채 정산을 발표했습니다: 100,000달러 부채를 상환하기 위해 주당 0.05달러에 2,000,000주 보통주를 발행하고, 주당 0.0355달러에 676,000주 보통주를 통해 24,000달러 부채를 정산하는 제안입니다.
Venowave는 하체의 혈관 및 림프 흐름을 개선하는 Medicare 및 Medicaid 적격 장치입니다. 이 FDA 지정 내구성 의료기기는 충전식 1.5V NiMH AA 배터리로 작동하며 다수 환자 사용을 위해 설계되었습니다.
Therma Bright Inc. (TSXV : THRM) (OTCQB : TBRIF) a obtenu un nouveau client avec une commande initiale de 200 unités de son produit Venowave VW5. La commande provient d'un distributeur clé dans le secteur des équipements médicaux durables, avec un potentiel important de commandes supplémentaires après un lancement réussi sur le marché dans les deux prochains mois.
L'entreprise a également annoncé deux règlements de dettes : l'émission de 2 000 000 d'actions ordinaires à 0,05 $ chacune pour régler une dette de 100 000 $, ainsi qu'une proposition de règlement d'une dette de 24 000 $ par l'émission de 676 000 actions ordinaires à 0,0355 $ chacune.
Venowave est un dispositif éligible Medicare et Medicaid qui améliore le flux vasculaire et lymphatique dans les membres inférieurs. Cet équipement médical durable, approuvé par la FDA, fonctionne avec une batterie rechargeable NiMH AA de 1,5 V et est conçu pour une utilisation multi-patients.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) hat einen neuen Kunden gewonnen, der eine Erstbestellung von 200 Einheiten seines Produkts Venowave VW5 aufgegeben hat. Die Bestellung stammt von einem wichtigen Distributor im Bereich der langlebigen medizinischen Geräte, mit Potenzial für bedeutende Folgeaufträge nach einem erfolgreichen Markteintritt in den nächsten zwei Monaten.
Das Unternehmen gab außerdem zwei Schuldenvereinbarungen bekannt: Ausgabe von 2.000.000 Stammaktien zu je 0,05 $ zur Begleichung einer Schuld von 100.000 $ sowie ein vorgeschlagener Ausgleich einer Schuld von 24.000 $ durch 676.000 Stammaktien zu je 0,0355 $.
Venowave ist ein Medicare- und Medicaid-zugelassenes Gerät, das den Gefäß- und Lymphfluss in den unteren Gliedmaßen verbessert. Dieses von der FDA zugelassene langlebige medizinische Gerät wird mit einer wiederaufladbaren 1,5V NiMH AA-Batterie betrieben und ist für den Mehrpatientengebrauch konzipiert.
- Secured new customer and initial order for 200 Venowave units
- Potential for significant follow-on orders after market launch
- Product qualifies for Medicare and Medicaid reimbursement
- Issuing 2.68M new shares for debt settlements, indicating financial strain
- Settling debt at low share prices ($0.05 and $0.0355) suggesting weak market valuation
Toronto, Ontario--(Newsfile Corp. - April 24, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce the successful signing of a new customer, resulting in an initial purchase order for 200 units of its flagship Venowave VW5 product, ("Venowave").
This purchase order underscores the continued demand for Venowave and the strength of the Company's product offering despite a challenging global business environment. The new customer, a key distributor within the Durable Medical Equipment sector, will be introducing Venowave to their established customer base.
Early indications following this initial order and a successful market launch over the next two months suggest the potential for significant follow-on orders of Venowave. Therma Bright is optimistic about the prospects of this new partnership and the opportunity to further expand the reach of its innovative medical device.
Rob Fia, CEO, commented: "This initial order is a testament to the value proposition of Venowave and the dedication of our team. We are excited to partner with this new distributor and look forward to the potential for substantial growth in this channel."
Therma Bright remains committed to navigating the evolving global trade environment and will continue to explore all available options to ensure the consistent and cost-effective delivery of its products to the market.
Further updates regarding the progress of this new business relationship and subsequent order volumes will be provided as they become available.
Therma Bright also announces that further to its press release of January 9, 2025, it has now issued 2,000,000 common shares at a deemed price of
The Company also announces that it has negotiated a debt settlement with an arm's length creditor pursuant to which it proposes to settle aggregate debt of
Venowave, which qualifies for Medicare and Medicaid HCPCS code reimbursement under 10 medical indications, is a compact, battery-operated peristaltic pump designed to enhance vascular and lymphatic flow in the lower limbs. When strapped below the knee, the device generates a wave-form motion that compresses the calf, promoting upward displacement of venous and lymphatic fluid. Powered by a single rechargeable 1.5V NiMH AA battery, the FDA-designated Durable Medical Equipment (DME) device allows users to receive treatment while staying active. The Venowave is built for durability and supports repeated use across multiple patients.
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as current and future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249651
FAQ
What is the size of Therma Bright's (TBRIF) new Venowave purchase order?
How many shares is TBRIF issuing for debt settlement in April 2025?
What medical reimbursements are available for Therma Bright's Venowave device?
When will the hold period expire for TBRIF's debt settlement shares?
